Alembic Pharmaceuticals Limited

BSE:533573 Stock Report

Market Cap: ₹182.1b

Alembic Pharmaceuticals Management

Management criteria checks 3/4

Alembic Pharmaceuticals' CEO is Chirayu Amin, appointed in Apr 2016, has a tenure of 9.58 years. total yearly compensation is ₹140.60M, comprised of 64.4% salary and 35.6% bonuses, including company stock and options. directly owns 2.63% of the company’s shares, worth ₹4.79B. The average tenure of the management team and the board of directors is 2.3 years and 8.1 years respectively.

Key information

Chirayu Amin

Chief executive officer

₹140.6m

Total compensation

CEO salary percentage64.44%
CEO tenure9.6yrs
CEO ownership2.6%
Management average tenure2.3yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chirayu Amin's remuneration changed compared to Alembic Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

₹6b

Jun 30 2025n/an/a

₹6b

Mar 31 2025₹141m₹91m

₹6b

Dec 31 2024n/an/a

₹6b

Sep 30 2024n/an/a

₹6b

Jun 30 2024n/an/a

₹6b

Mar 31 2024₹194m₹94m

₹6b

Dec 31 2023n/an/a

₹6b

Sep 30 2023n/an/a

₹5b

Jun 30 2023n/an/a

₹5b

Mar 31 2023₹88m₹88m

₹3b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹3b

Jun 30 2022n/an/a

₹3b

Mar 31 2022₹280m₹80m

₹5b

Dec 31 2021n/an/a

₹8b

Sep 30 2021n/an/a

₹9b

Jun 30 2021n/an/a

₹10b

Mar 31 2021₹315m₹65m

₹11b

Dec 31 2020n/an/a

₹12b

Sep 30 2020n/an/a

₹11b

Jun 30 2020n/an/a

₹10b

Mar 31 2020₹265m₹65m

₹8b

Dec 31 2019n/an/a

₹7b

Sep 30 2019n/an/a

₹7b

Jun 30 2019n/an/a

₹6b

Mar 31 2019₹255m₹55m

₹6b

Compensation vs Market: Chirayu's total compensation ($USD1.59M) is above average for companies of similar size in the Indian market ($USD540.80K).

Compensation vs Earnings: Chirayu's compensation has been consistent with company performance over the past year.

CEO

Chirayu Amin (79 yo)

9.6yrs
Tenure
₹140,600,000
Compensation

Mr. Chirayu Ramanbhai Amin, M.B.A. (U.S.A.), has been Chief Executive Officer of Alembic Pharmaceuticals Limited since April 27, 2016. Mr. Amin served as Managing Director of Alembic Pharmaceuticals Limite...

Leadership Team

NamePositionTenureCompensationOwnership
Chirayu Amin
Executive Chairman & CEO9.6yrs₹140.60m2.63%
₹ 4.8b
Shaunak Amin
MD & Executive Director10.6yrs₹191.30m0.51%
₹ 933.2m
Raj Kumar Baheti
Executive Directorno data₹82.80mno data
Pranav Amin
MD & Executive Director1.7yrs₹191.30m0.51%
₹ 935.9m
G. Krishnan
Chief Financial Officerless than a yearno datano data
Sachin Ghosalkar
Senior Vice President of SCM & Operationsless than a yearno datano data
J. Raman
Chief Scientific Officerno data₹8.41mno data
Manisha Saraf
Company Secretary & Compliance Officer2.6yrsno datano data
Amresh Choudhary
Head-Legal & Taxationno datano datano data
Udit Amin
Chief Business Development Officerno data₹8.30m0.51%
₹ 933.1m
Ajay Desai
Senior Vice President of Financeno data₹9.20mno data
Nilesh Wadhwa
Head of International Business & Strategy2.3yrsno datano data
2.3yrs
Average Tenure
55yo
Average Age

Experienced Management: 533573's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chirayu Amin
Executive Chairman & CEO15.4yrs₹140.60m2.63%
₹ 4.8b
Shaunak Amin
MD & Executive Director12.5yrs₹191.30m0.51%
₹ 933.2m
Raj Kumar Baheti
Executive Director15.4yrs₹82.80mno data
Pranav Amin
MD & Executive Director14.7yrs₹191.30m0.51%
₹ 935.9m
Manish Kejriwal
Independent Director1.7yrs₹2.76mno data
Ashok Barat
Independent Director3.8yrs₹3.05mno data
Jai Diwanji
Independent Director2.5yrs₹2.79mno data
Geeta Goradia
Independent Directorless than a year₹300.00kno data
8.1yrs
Average Tenure
61.5yo
Average Age

Experienced Board: 533573's board of directors are considered experienced (8.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/10 02:44
End of Day Share Price 2025/11/10 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alembic Pharmaceuticals Limited is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAntique Stockbroking Ltd.
Harith AhamedAvendus Spark
Vijayaraghavan SwaminathanAvendus Spark